Lowest-Rated StocksLowest-RatedNegative News SentimentNegative News Doximity Stock Price, News & Analysis (NASDAQ:DOCS) $24.35 +1.10 (+4.73%) (As of 12/1/2023 ET) Add Compare Share Share Today's Range$23.14▼$24.3850-Day Range$19.86▼$25.4152-Week Range$19.71▼$40.12Volume1.45 million shsAverage Volume2.25 million shsMarket Capitalization$4.53 billionP/E Ratio41.98Dividend YieldN/APrice Target$28.40 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsSocial Media Doximity MarketRank™ Stock AnalysisAnalyst RatingHold2.00 Rating ScoreUpside/Downside16.6% Upside$28.40 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingSelling Shares$104,055 Sold Last QuarterProj. Earnings Growth8.70%From $0.69 to $0.75 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.93 out of 5 starsMedical Sector650th out of 951 stocksCustom Computer Programming Services Industry18th out of 27 stocks 2.0 Analyst's Opinion Consensus RatingDoximity has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 2 buy ratings, 5 hold ratings, and 2 sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $28.40, Doximity has a forecasted upside of 16.6% from its current price of $24.35.Amount of Analyst CoverageDoximity has only been the subject of 3 research reports in the past 90 days. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for DOCS. Previous Next 0.0 Dividend Strength Dividend YieldDoximity does not currently pay a dividend.Dividend GrowthDoximity does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for DOCS. Previous Next 1.1 News and Social Media Coverage News SentimentDoximity has a news sentiment score of -1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.76 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Doximity this week, compared to 3 articles on an average week.Search Interest28 people have searched for DOCS on MarketBeat in the last 30 days. This is an increase of 180% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Doximity insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $104,055.00 in company stock.Percentage Held by Insiders39.40% of the stock of Doximity is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions54.65% of the stock of Doximity is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 2.5 Earnings and Valuation Earnings GrowthEarnings for Doximity are expected to grow by 8.70% in the coming year, from $0.69 to $0.75 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Doximity is 41.98, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 114.54.Price to Earnings Ratio vs. SectorThe P/E ratio of Doximity is 41.98, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 101.32.Price to Earnings Growth RatioDoximity has a PEG Ratio of 3.86. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioDoximity has a P/B Ratio of 5.19. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Doximity Stock (NASDAQ:DOCS)Doximity, Inc. operates a cloud-based digital platform for medical professionals in the United States. The company's platform provides its members with tools built for medical professionals, enabling them to collaborate with their colleagues, coordinate patient care, conduct virtual patient visits, stay up to date with the latest medical news and research, and manage their careers. It primarily serves pharmaceutical manufacturers and healthcare systems. The company was formerly known as 3MD Communications, Inc. and changed its name to Doximity, Inc. in June 2010. Doximity, Inc. was incorporated in 2010 and is headquartered in San Francisco, California.Read More DOCS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart DOCS Stock News HeadlinesNovember 24, 2023 | msn.com3 Medical Services Stocks to Buy as Industry Trends ImproveNovember 23, 2023 | americanbankingnews.comDoximity, Inc. (NASDAQ:DOCS) Receives Consensus Recommendation of "Hold" from AnalystsDecember 2, 2023 | Wealthpress (Ad)Trading Experts Call It “The Perfect Tesla Trade”Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.November 17, 2023 | morningstar.comDoximity Inc Class ANovember 13, 2023 | markets.businessinsider.comReiterated Sell Rating for Doximity Amid Conservative Growth and Challenging Macro EnvironmentNovember 12, 2023 | markets.businessinsider.comPiper Sandler Keeps Their Hold Rating on Doximity (DOCS)November 11, 2023 | finance.yahoo.comDoximity, Inc. (NYSE:DOCS) Q2 2024 Earnings Call TranscriptNovember 11, 2023 | msn.comDoximity (NYSE:DOCS) Surges after Q2 Results Beat EstimatesDecember 2, 2023 | Wealthpress (Ad)Trading Experts Call It “The Perfect Tesla Trade”Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.November 10, 2023 | nasdaq.comDoximity Shares Climbs On Growth In Q2 Profit Above Estimates, OutlookNovember 10, 2023 | msn.comThese Stocks Are Moving the Most Today: Plug Power, Trade Desk, Illumina, Doximity, Wynn, Hologic, and MoreNovember 10, 2023 | msn.comDoximity posts record gain after Q2 beat and guidance raiseNovember 10, 2023 | benzinga.comDoximity Options Trading: A Deep Dive into Market SentimentNovember 10, 2023 | finance.yahoo.comDoximity (DOCS) Shares Skyrocket, What You Need To KnowNovember 10, 2023 | msn.comDoximity Stock Rallies. Guidance Boost ‘Just What the Doctor Ordered.’November 10, 2023 | seekingalpha.comDoximity Earnings: Steer Clear Of This Rollercoaster War Of Optimism Vs. SkepticismNovember 9, 2023 | benzinga.comDoximity: Q2 Earnings InsightsNovember 9, 2023 | msn.comOnline Networking Service Doximity Stock Soars On Q2 Performance - Here's WhyNovember 4, 2023 | morningstar.comDoximity Inc Class A DOCSNovember 2, 2023 | finance.yahoo.comDoximity, Inc. (DOCS) Interactive Stock Chart - Yahoo FinanceNovember 1, 2023 | finance.yahoo.comDoximity Launches DocDefender, Expanding Services to Safeguard Physician PrivacyOctober 31, 2023 | seekingalpha.comDoximity: Adding Value Using AI But Faces Near-Term RisksOctober 31, 2023 | finance.yahoo.comA Weaker Growth Outlook Dragged Doximity (DOCS)October 23, 2023 | finance.yahoo.comWill Weakness in Doximity, Inc.'s (NYSE:DOCS) Stock Prove Temporary Given Strong Fundamentals?October 12, 2023 | benzinga.comSHAREHOLDER ALERT: The Law Offices of Vincent Wong Investigate Doximity, Inc. (DOCS) for Potential Violations of Securities LawsOctober 12, 2023 | theglobeandmail.comUnpacking Q2 Earnings: Doximity (NYSE:DOCS) In The Context Of Other Vertical Software StocksOctober 7, 2023 | finance.yahoo.comThese 2 Top Stocks Are Screaming Buys Right NowSee More Headlines Receive DOCS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Doximity and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/09/2023Today12/02/2023Next Earnings (Estimated)2/08/2024Fiscal Year End3/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Custom computer programming services Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:DOCS CUSIPN/A CIK1516513 Webwww.doximity.com Phone650-549-4330FaxN/AEmployees977Year FoundedN/APrice Target and Rating Average Stock Price Target$28.40 High Stock Price Target$45.00 Low Stock Price Target$21.00 Potential Upside/Downside+16.6%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)$0.58 Trailing P/E Ratio41.98 Forward P/E Ratio35.29 P/E Growth3.86Net Income$112.82 million Net Margins27.47% Pretax Margin33.88% Return on Equity14.26% Return on Assets12.23% Debt Debt-to-Equity RatioN/A Current Ratio7.00 Quick Ratio7.00 Sales & Book Value Annual Sales$419.05 million Price / Sales10.80 Cash Flow$0.75 per share Price / Cash Flow32.37 Book Value$4.69 per share Price / Book5.19Miscellaneous Outstanding Shares185,910,000Free Float112,660,000Market Cap$4.53 billion OptionableNot Optionable Beta1.11 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesMr. Jeffrey A. Tangney (Age 50)Co-Founder, CEO & Chairperson Comp: $243.73kDr. Nate Gross M.D. (Age 39)Co-Founder & Chief Strategy Officer Comp: $455.54kMs. Anna Bryson (Age 33)Chief Financial Officer Comp: $453.71kMs. Jennifer W. Chaloemtiarana (Age 55)General Counsel & Corporate Secretary Comp: $504.04kMr. Paul Jorgensen (Age 52)Chief Revenue Officer Comp: $455.13kMs. Shari BuckCo-founder and SVP People & OpsMr. Jey BalachandranChief Technology OfficerMr. Perry Scott GoldHead of Investor RelationsJim RivasHead of Corporate CommunicationsMr. Bruno MirandaSenior VP of EngineeringMore ExecutivesKey CompetitorsCerevel TherapeuticsNASDAQ:CEREagilon healthNYSE:AGLQuidelOrthoNASDAQ:QDELLantheusNASDAQ:LNTHImmunoGenNASDAQ:IMGNView All CompetitorsInsiders & InstitutionsWellington Management Group LLPBought 25,034 shares on 12/1/2023Ownership: 0.013%American Century Companies Inc.Bought 19,898 shares on 11/30/2023Ownership: 0.166%Neo Ivy Capital ManagementBought 5,136 shares on 11/30/2023Ownership: 0.003%Kira Scherer WamplerSold 2,500 sharesTotal: $61,025.00 ($24.41/share)Comerica BankBought 62,613 shares on 11/21/2023Ownership: 0.034%View All Insider TransactionsView All Institutional Transactions DOCS Stock Analysis - Frequently Asked Questions Should I buy or sell Doximity stock right now? 9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Doximity in the last year. There are currently 2 sell ratings, 5 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" DOCS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in DOCS, but not buy additional shares or sell existing shares. View DOCS analyst ratings or view top-rated stocks. What is Doximity's stock price target for 2024? 9 analysts have issued 12 month target prices for Doximity's stock. Their DOCS share price targets range from $21.00 to $45.00. On average, they anticipate the company's stock price to reach $28.40 in the next twelve months. This suggests a possible upside of 16.6% from the stock's current price. View analysts price targets for DOCS or view top-rated stocks among Wall Street analysts. How have DOCS shares performed in 2023? Doximity's stock was trading at $33.56 at the beginning of the year. Since then, DOCS stock has decreased by 27.4% and is now trading at $24.35. View the best growth stocks for 2023 here. When is Doximity's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, February 8th 2024. View our DOCS earnings forecast. How were Doximity's earnings last quarter? Doximity, Inc. (NASDAQ:DOCS) released its earnings results on Thursday, November, 9th. The company reported $0.18 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.13 by $0.05. The business earned $113.61 million during the quarter, compared to analyst estimates of $109.19 million. Doximity had a net margin of 27.47% and a trailing twelve-month return on equity of 14.26%. What ETFs hold Doximity's stock? ETFs with the largest weight of Doximity (NASDAQ:DOCS) stock in their portfolio include Jacob Forward ETF (JFWD), Global X Telemedicine & Digital Health ETF (EDOC), Fidelity Digital Health ETF (FDHT), First Trust Nasdaq Lux Digital Health Solutions ETF (EKG), Janus Henderson Small/Mid Cap Growth Alpha ETF (JSMD), Syntax Stratified MidCap ETF (SMDY), Natixis U.S. Equity Opportunities ETF (EQOP) and BlackRock Future Innovators ETF (BFTR). When did Doximity IPO? (DOCS) raised $501 million in an initial public offering (IPO) on Thursday, June 24th 2021. The company issued 23,300,000 shares at a price of $20.00-$23.00 per share. Morgan Stanley, Goldman Sachs and J.P. Morgan Securities acted as the underwriters for the IPO and Piper Sandler, William Blair, Canaccord and Raymond James were co-managers. Who are Doximity's major shareholders? Doximity's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Morgan Stanley (3.81%), Baillie Gifford & Co. (3.42%), Clearbridge Investments LLC (3.10%), Loomis Sayles & Co. L P (1.38%), FMR LLC (1.07%) and Bank of New York Mellon Corp (0.63%). Insiders that own company stock include Anna Bryson, Craig Overpeck, Gilbert H Kliman, Interwest Partners X Lp, Joseph B Kleine, Kevin Spain, Kira Scherer Wampler, Paul W Jorgensen and Timothy S Cabral. View institutional ownership trends. How do I buy shares of Doximity? Shares of DOCS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:DOCS) was last updated on 12/2/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Doximity, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.